Last reviewed 2026-05-14 · How we verify

Intravenous injection of 177Lu-octreotate

Intravenous injection of 177Lu-octreotate is a Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT) Small molecule drug developed by Jules Bordet Institute. It is currently in Phase 3 development for Neuroendocrine tumors (NET) with somatostatin receptor expression, Gastroenteropancreatic neuroendocrine tumors (GEP-NET). Also known as: 177Lu-DOTATATE, Lutate.

177Lu-octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy to kill them.

177Lu-octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy to kill them. Used for Neuroendocrine tumors (NET) with somatostatin receptor expression, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).

At a glance

Mechanism of action

Octreotate is a peptide that mimics somatostatin and binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells. When labeled with the beta-emitting radioisotope lutetium-177, it delivers cytotoxic radiation directly to tumor cells while sparing normal tissues, resulting in cell death through DNA damage.

Approved indications

• Neuroendocrine tumors (NET) with somatostatin receptor expression
• Gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Common side effects

• Nausea and vomiting
• Hematologic toxicity (anemia, thrombocytopenia, leukopenia)
• Renal toxicity
• Hepatic toxicity
• Fatigue

Key clinical trials

• Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (PHASE2)
• 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (PHASE3)
• Randomized Phase III of PRRT Versus Interferon (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Intravenous injection of 177Lu-octreotate CI brief — competitive landscape report
• Intravenous injection of 177Lu-octreotate updates RSS · CI watch RSS
• Jules Bordet Institute portfolio CI

Frequently asked questions about Intravenous injection of 177Lu-octreotate

Related

• Drug class: All Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT) drugs
• Target: All drugs targeting Somatostatin receptor 2 (SSTR2)
• Manufacturer: Jules Bordet Institute — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Neuroendocrine tumors (NET) with somatostatin receptor expression
• Indication: Drugs for Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
• Also known as: 177Lu-DOTATATE, Lutate
• Compare: Intravenous injection of 177Lu-octreotate vs similar drugs
• Pricing: Intravenous injection of 177Lu-octreotate cost, discount & access